A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.
Sanoff HK, Deal AM, Patel J, Sorah JD, Gaddy J, O'Neil B, Turk A, Irvin W, Boles J, Lee MS, McRee A, Wardell AC, Weck KE, Basch E, Wood WA, Innocenti F.
Sanoff HK, et al.
Oncologist. 2024 Sep 6;29(9):786-793. doi: 10.1093/oncolo/oyae122.
Oncologist. 2024.
PMID: 38837045
Free PMC article.
Clinical Trial.